Detalles de la búsqueda
1.
Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy.
Br J Clin Pharmacol
; 88(7): 3182-3192, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35029306
2.
A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody-drug conjugate, in patients with advanced or metastatic cancer.
Invest New Drugs
; 39(6): 1613-1623, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34264412
3.
Post hoc analyses of GOG 9923: Does BRCA status affect toxicities?: An NRG oncology study.
Gynecol Oncol
; 161(2): 512-515, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33610319
4.
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 21(1): 105-120, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31753727
5.
A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer.
Gynecol Oncol
; 156(1): 13-22, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31708167
6.
Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer.
Genes Dev
; 25(23): 2465-79, 2011 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-22156207
7.
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial.
Lancet
; 390(10109): 2266-2277, 2017 Nov 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-28916371
8.
A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors.
Invest New Drugs
; 36(6): 1016-1025, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29611022
9.
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Lancet Oncol
; 18(1): 75-87, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27908594
10.
A Phase 2, Single Arm Study of Iniparib in Patients With BRCA1 or BRCA2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Int J Gynecol Cancer
; 26(2): 255-60, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26745694
11.
Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients.
Commun Med (Lond)
; 3(1): 154, 2023 Oct 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-37880389
12.
Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
Gynecol Oncol
; 125(3): 621-4, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22446622
13.
Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial.
Nat Commun
; 13(1): 1878, 2022 04 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35388003
14.
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
Lancet
; 376(9737): 245-51, 2010 Jul 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-20609468
15.
A phase II, single-arm study of the anti-α5ß1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer.
Gynecol Oncol
; 121(2): 273-9, 2011 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21276608
16.
Efficacy and safety of first-line veliparib and carboplatin-paclitaxel in patients with HER2- advanced germline BRCA+ breast cancer: Subgroup analysis of a randomised clinical trial.
Eur J Cancer
; 154: 35-45, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34243076
17.
Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer.
Gynecol Oncol
; 115(2): 209-14, 2009 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-19664812
18.
Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumor growth and invasiveness in a mouse model of multistage cancer.
Cancer Res
; 67(15): 7378-85, 2007 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-17671208
19.
Proceedings from the 9th International Conference on Ovarian Cancer.
Gynecol Oncol
; 125(1): 5-7, 2012 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-22210309
20.
Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy.
Clin Cancer Res
; 23(8): 1955-1966, 2017 04 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27702821